ELLA

Peak

ulipristal acetate

NDAORALTABLET
Approved
Aug 2010
Lifecycle
Peak
Competitive Pressure
8/100
Clinical Trials
20

Mechanism of Action

occur, ella postpones follicular rupture. The likely primary mechanism of action of ulipristal acetate for emergency contraception is therefore inhibition or delay of ovulation; however, alterations to the endometrium that may affect implantation may also contribute to efficacy.

Clinical Trials (5)

NCT07406360Phase 3Not Yet Recruiting

A Study on the Immune Response and Safety of an Investigational Combined Measles, Mumps, Rubella and Varicella Vaccine, When Administered as Intramuscular Injection to Healthy Children 15 Months to 6 Years of Age

Started Apr 2026
1,209 enrolled
Measles
NCT07434128Phase 2Not Yet Recruiting

Mammogram Pretreatment With Ulipristal Acetate

Started Apr 2026
26 enrolled
Mammography ScreeningBreast Density
NCT06965504N/ANot Yet Recruiting

INitiation and Titration of Guideline Directed Medical TheRApy in HearT Failure Cardiogenic Shock With ImpElla 5.5 for Cardiac Recovery

Started Apr 2026
60 enrolled
Heart FailureCardiogenic ShockReduced Ejection Fraction Heart Failure
NCT07286370Phase 2Not Yet Recruiting

A Study to Evaluate Safety, Reactogenicity, and Immune Response of GVGH iNTS-TCV Vaccine Against Invasive Nontyphoidal Salmonella Disease and Typhoid Fever in Infants

Started Feb 2026
537 enrolled
Salmonella Infections
NCT07320716Phase 2Not Yet Recruiting

Long-Term Immunogenicity of the altSonflex1-2-3 Shigella Vaccine in African Children

Started Jan 2026
528 enrolled
Diarrhoea

Loss of Exclusivity

LOE Date
Jun 12, 2030
52 months away
Patent Expiry
Jun 12, 2030

Patent Records (5)

Patent #ExpiryTypeUse Code
9844510
Dec 8, 2028
Product
8735380
Feb 20, 2029
Product
10159681
Apr 13, 2030
U-2510
9283233
Apr 13, 2030
U-1821
10772897
Apr 13, 2030
U-2958